Zyprexa news | Breaking Zyprexa news | Zyprexa

Eli Lilly Dodges Woes Bedeviling Industry

...Lilly's primary growth driver, antidepressant Cymbalta, has slowed lately and safety concerns have clipped sales of attention deficit disorder drug Strattera."Lilly has been more innovative than most other companies but done worse at execution," said Barbara Ryan an analyst at Deutsche Bank.

"There's betting on a pipeline that hasn't panned out in the past."In each of the last four years, analysts earnings projections fell through the 12 months, according to Zacks, reflecting negative developments or sentiment."The company is not without controversy," said Schott.

Yet, he is willing to trust Lilly because he likes the management and the strategy.Born in Morocco and fluent in four languages, Taurel is a favorite among analysts for his direct but personable style.

CONTINUED 1 2 Next > Print This ArticleE-Mail This ArticleRSS Feed © 2006 The Associated Press Featured Advertiser Links PowerPoint Free Onlin...

Read more...

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | All news

Medicine   Health and Fitness